Schrodinger: More Than An AI Bubble Stock (NASDAQ:SDGR)

Schrodinger's stock has surged this year due to AI hype and the strength of its drug discovery business, with its physics-based software platform offering accurate predictions of molecule properties and increasing the odds of finding suitable molecules, presenting a potentially valuable opportunity for investors.

seekingalpha.com

Relevant topic timeline:

9/13/2023

Bill Gates Bets on AI Drug Discovery Company Schrödinger Despite Some Caution Signs

Bill Gates has invested in Schrödinger, an AI-focused drug discovery company, and Wall Street analysts are bullish about its stock, with a potential upside of 67% over the next 12 months, but there are some concerns about the company's revenue, profitability, and customer collaborations.